Compare PCG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCG | ILMN |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0B | 32.3B |
| IPO Year | 2000 | 2000 |
| Metric | PCG | ILMN |
|---|---|---|
| Price | $14.15 | $218.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 17 |
| Target Price | $22.19 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 42.8M | 1.7M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | 2.61 | ★ 170.87 |
| EPS | 0.72 | ★ 2.22 |
| Revenue | ★ $24,935,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | $7.24 | $6.47 |
| Revenue Next Year | $3.41 | $5.58 |
| P/E Ratio | ★ $19.45 | $98.09 |
| Revenue Growth | ★ 2.11 | N/A |
| 52 Week Low | $12.59 | $88.00 |
| 52 Week High | $19.16 | $231.81 |
| Indicator | PCG | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 33.05 | 59.45 |
| Support Level | N/A | $117.73 |
| Resistance Level | $16.82 | $231.81 |
| Average True Range (ATR) | 0.80 | 9.22 |
| MACD | -0.50 | -0.37 |
| Stochastic Oscillator | 24.33 | 68.24 |
PG&E is a holding company whose main subsidiary is Pacific Gas and Electric, a regulated utility operating in Central and Northern California that serves 5.3 million electricity customers and 4.6 million gas customers in 47 of the state's 58 counties. PG&E operated under bankruptcy court supervision in 2001-04 during California's energy crisis and in 2019-20 due to wildfire losses. In 2004, PG&E sold its unregulated assets as part of its first postbankruptcy reorganization.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.